{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:53:22Z","timestamp":1778547202835,"version":"3.51.4"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Real\u2010world data on the first\u2010line treatment of patients with advanced non\u2010small cell lung cancer (NSCLC) are still limited. The NEPTUN study evaluated effectiveness and safety of first\u2010line <jats:italic>nab<\/jats:italic>\u2010paclitaxel (Abraxane) plus carboplatin (<jats:italic>nab<\/jats:italic>\u2010P\/C) in patients with advanced NSCLC in routine clinical practice in Germany. Patients included in our study were aged \u226518\u2009years, diagnosed with locally advanced or metastatic NSCLC and with decision for first\u2010line <jats:italic>nab<\/jats:italic>\u2010P\/C in routine clinical practice. Primary objective was 6\u2010month progression\u2010free survival rate (PFS6), secondary objectives included overall survival (OS), overall response rate (ORR) and safety. From 2016 to 2019, 408 patients from 75 sites were enrolled. PFS6 was 39.5% (95% CI: 34.2\u201044.8), median PFS was 5.1\u00a0months (95% CI: 4.6\u20105.6), ORR was 42.9% (95% CI: 37.7\u201048.2). Median OS was 10.5\u00a0months (95% CI: 9.2\u201011.6). In subgroup analyses, median OS for squamous vs non\u2010squamous histology was 11.5\u00a0months (95% CI: 9.2\u201013.8) vs 9.8\u00a0months (95% CI: 8.1\u201011.3) and for patients aged \u226570 vs &lt;70\u2009years median OS was 12.4\u00a0months (95% CI: 9.8\u201015.1) vs 9.6\u00a0months (95% CI: 7.7\u201011.1). Adverse events (AEs) related to <jats:italic>nab<\/jats:italic>\u2010paclitaxel were reported in 247 (66.4%) patients, while carboplatin\u2010related AEs were documented in 224 (60.2%) patients. Most frequently related AEs were leukopenia (22.3%) for <jats:italic>nab<\/jats:italic>\u2010paclitaxel and anemia (20.2%) for carboplatin. <jats:italic>N<\/jats:italic><jats:italic>ab<\/jats:italic>\u2010P\/C\u2010related deaths were reported in 2 (0.5%) patients (sepsis and neutropenic sepsis). No new or unexpected safety signals emerged. These results support the effectiveness and safety of first\u2010line <jats:italic>nab<\/jats:italic>\u2010P\/C in patients with advanced NSCLC reported in the pivotal trial and highlight the clinical value of this regimen in the real\u2010world setting.<\/jats:p>","DOI":"10.1002\/ijc.34467","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T13:53:40Z","timestamp":1675950820000},"page":"141-152","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["<scp>First\u2010line<\/scp><i>nab<\/i>\u2010paclitaxel plus carboplatin for patients with advanced non\u2010small cell lung cancer: Final results of the <scp>NEPTUN<\/scp> study"],"prefix":"10.1002","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8976-7328","authenticated-orcid":false,"given":"Tobias","family":"Dechow","sequence":"first","affiliation":[{"name":"Praxis f\u00fcr Onkologie Ravensburg  Ravensburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Riera\u2010Knorrenschild","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr H\u00e4matologie, Onkologie und Immunologie Universit\u00e4tsklinikum Gie\u00dfen und Marburg GmbH  Marburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Hackanson","sequence":"additional","affiliation":[{"name":"Medizinische Klinik II Universit\u00e4tsklinikum Augsburg  Augsburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Janssen","sequence":"additional","affiliation":[{"name":"Praxis f\u00fcr H\u00e4matologie und Onkologie  Westerstede Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Schulz","sequence":"additional","affiliation":[{"name":"Praxis f\u00fcr Internistische Onkologie und H\u00e4matologie  Frechen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Oppermann","sequence":"additional","affiliation":[{"name":"Medical Department iOMEDICO, Medical Department  Freiburg im Breisgau Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Chiabudini","sequence":"additional","affiliation":[{"name":"Biostatistik iOMEDICO, Biostatistik  Freiburg im Breisgau Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludwig Fischer","family":"von Weikersthal","sequence":"additional","affiliation":[{"name":"Praxis f\u00fcr H\u00e4matologie und Internistische Onkologie Gesundheitszentrum St. Marien GmbH  Amberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Budweiser","sequence":"additional","affiliation":[{"name":"Medizinische Klinik III Klinikum Rosenheim  Rosenheim Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Nacke","sequence":"additional","affiliation":[{"name":"Praxis f\u00fcr H\u00e4matologie und Onkologie  Remagen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Taeuscher","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Pneumologie\/Infektiologie, H\u00e4matologie\/Onkologie, Rheumatologie SRH Wald\u2010Klinikum Gera GmbH  Gera Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Welslau","sequence":"additional","affiliation":[{"name":"H\u00e4mato\u2010Onkologische Schwerpunktpraxis Klinikum Aschaffenburg GmbH  Aschaffenburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Potthoff","sequence":"additional","affiliation":[{"name":"Medical Department iOMEDICO, Medical Department  Freiburg im Breisgau Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00761-018-0480-2"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-16483-5_6893"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.07.025"},{"key":"e_1_2_13_5_1","unstructured":"Lung Cancer \u2010 Lung Cancer Europe [Internet].https:\/\/www.lungcancereurope.eu\/lung-cancer\/. Accessed September 20 2021."},{"key":"e_1_2_13_6_1","unstructured":"Browse the Tables and Figures \u2010 SEER Cancer Statistics Review (CSR) 1975\u20102014 [Internet].https:\/\/seer.cancer.gov\/archive\/csr\/1975_2014\/browse_csr.php?sectionSEL=15&pageSEL=sect_15_table.14.html. Accessed September 30 2021."},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0013"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30958-8"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy292.050"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.11.111"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174"},{"key":"e_1_2_13_13_1","first-page":"579","article-title":"Subgroup analysis of the non\u2010interventional REASON study: PFS and OS according to age, smoking history, gender, and histology in NSCLC patients treated with Gefitinib or chemotherapy","volume":"70","author":"Schuette W","year":"2016","journal-title":"Pneumologie"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181ba3634"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03022"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.5848"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00253"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00262"},{"key":"e_1_2_13_20_1","unstructured":"EuroQol Research Foundation.EQ\u20105D\u20105L User Guide [Internet];2019.https:\/\/euroqol.org\/publications\/user-guides"},{"key":"e_1_2_13_21_1","unstructured":"FACIT.org.FACT\u2010L User Guide."},{"key":"e_1_2_13_22_1","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) [Internet].http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt235"},{"key":"e_1_2_13_24_1","first-page":"207","article-title":"Paclitaxel\/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy","volume":"8","author":"Thomas M","year":"2017","journal-title":"Lung Cancer"},{"key":"e_1_2_13_25_1","unstructured":"Updated analysis of KEYNOTE\u2010024: pembrolizumab versus platinum\u2010based chemotherapy for advanced non\u2010small\u2010cell lung cancer with PD\u2010L1 tumor proportion score of 50% or greater \u2010 PubMed [Internet].https:\/\/pubmed.ncbi.nlm.nih.gov\/30620668\/"},{"key":"e_1_2_13_26_1","unstructured":"Cemiplimab monotherapy for first\u2010line treatment of advanced non\u2010small\u2010cell lung cancer with PD\u2010L1 of at least 50%: a multicentre open\u2010label global phase 3 randomised controlled trial \u2010 PubMed [Internet].https:\/\/pubmed.ncbi.nlm.nih.gov\/33581821\/"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.03.028"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30641-0"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA4"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.34467","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.34467","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.34467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:51:45Z","timestamp":1692579105000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.34467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1002\/ijc.34467"],"URL":"https:\/\/doi.org\/10.1002\/ijc.34467","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"assertion":[{"value":"2022-07-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}